Search results
Showing 421 to 435 of 1244 results for pathway
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
This quality standard covers recognising, assessing and responding to abuse and neglect of children and young people under 18. It covers physical, sexual and emotional abuse. This quality standard describes high-quality care in priority areas for improvement.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.
View recommendations for IPG745Show all sections
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
This quality standard covers services for domestic violence and abuse in adults and young people (aged 16 and over). It includes identifying and supporting people experiencing domestic violence or abuse, as well as support for those who carry it out. It also covers children and young people (under 16) who are affected by domestic violence or abuse that is not carried out against them. It describes high-quality care in priority areas for improvement.
View quality statements for QS116Show all sections
Sections for QS116
- Quality statements
- Quality statement 1: Asking about domestic violence and abuse
- Quality statement 2: Response to domestic violence and abuse
- Quality statement 3: Referral to specialist support services for people experiencing domestic violence or abuse
- Quality statement 4: Referral to specialist services for people perpetrating domestic violence or abuse
- About this quality standard
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .